| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A recombinant partial protein sequence from the C-terminal region of the human protein was used as the immunogen for the IRF4 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
IRF4 Antibody / Interferon regulatory factor 4 / MUM1 is an antibody targeting IRF4. Host: Rabbit. Monoclonal. Clone: MUM1/8274R. Format: Purified. Applications: IHC-P.
Key elements and design rationale
- Target: IRF4.
- Immunogen: A recombinant partial protein sequence from the C-terminal region of the human protein was used as the immunogen for th….
- Species reactivity: Human.
- Localization: Nucleus.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
Interferon regulatory factor 4 (IRF4), also called Multiple myeloma oncogene 1 (MUM1) is one of nuclear transcription factors necessary for development and activation of B lymphocytes.
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
